Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes

Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong Min Liu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest class of drugs to be introduced for the treatment of type 2 diabetes mellitus. These drugs improve glycemic control by increasing urinary glucose excretion and exert additional benefits of weight loss and blood pressure reductions. Areas covered: This review outlines the background to SGLT2 inhibitors and provides details on the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin and discusses the cardiovascular outcome trial. Expert opinion: Empagliflozin was the first from a new group of antidiabetic drugs to show benefits in a cardiovascular outcome trial. There were significant reductions in cardiovascular and all-cause mortality and empagliflozin treatment reduced hospitalizations for heart failure and reduced the progression of diabetic nephropathy. These benefits, which occurred at a very early stage during the study, may be related to a reduction in circulating volume or changes in metabolic fuel utilization in the heart and kidneys. Whether these effects are shared by other SGLT2 inhibitors is not yet known, but there may be differences between drugs related to selectivity for inhibition of SGLT2 compared to SGLT1 or other pharmacological effects. Currently the outcome evidence is only available to support the use of empagliflozin in this drug class.

Original languageEnglish
Pages (from-to)211-223
Number of pages13
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Sodium-Glucose Transporter 2
Pharmacodynamics
Symporters
Pharmacokinetics
Medical problems
Type 2 Diabetes Mellitus
Glucose
Sodium
Pharmaceutical Preparations
Expert Testimony
Diabetic Nephropathies
Therapeutics
Hypoglycemic Agents
Blood pressure
Weight Loss
Hospitalization
Heart Failure
Pharmacology
Blood Pressure
Kidney

Keywords

  • Empagliflozin
  • SGLT2
  • sodium-glucose co-transporter 2 inhibitors
  • type 2 diabetes mellitus
  • urinary glucose excretion

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. / Tomlinson, Brian; Hu, Miao; Zhang, Yuzhen; Chan, Paul; Liu, Zhong Min.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 13, No. 2, 01.02.2017, p. 211-223.

Research output: Contribution to journalArticle

@article{1d7e01ba5f1f4a6f98777cb0e2f5d9f2,
title = "Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes",
abstract = "Introduction: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest class of drugs to be introduced for the treatment of type 2 diabetes mellitus. These drugs improve glycemic control by increasing urinary glucose excretion and exert additional benefits of weight loss and blood pressure reductions. Areas covered: This review outlines the background to SGLT2 inhibitors and provides details on the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin and discusses the cardiovascular outcome trial. Expert opinion: Empagliflozin was the first from a new group of antidiabetic drugs to show benefits in a cardiovascular outcome trial. There were significant reductions in cardiovascular and all-cause mortality and empagliflozin treatment reduced hospitalizations for heart failure and reduced the progression of diabetic nephropathy. These benefits, which occurred at a very early stage during the study, may be related to a reduction in circulating volume or changes in metabolic fuel utilization in the heart and kidneys. Whether these effects are shared by other SGLT2 inhibitors is not yet known, but there may be differences between drugs related to selectivity for inhibition of SGLT2 compared to SGLT1 or other pharmacological effects. Currently the outcome evidence is only available to support the use of empagliflozin in this drug class.",
keywords = "Empagliflozin, SGLT2, sodium-glucose co-transporter 2 inhibitors, type 2 diabetes mellitus, urinary glucose excretion",
author = "Brian Tomlinson and Miao Hu and Yuzhen Zhang and Paul Chan and Liu, {Zhong Min}",
year = "2017",
month = "2",
day = "1",
doi = "10.1080/17425255.2017.1258401",
language = "English",
volume = "13",
pages = "211--223",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes

AU - Tomlinson, Brian

AU - Hu, Miao

AU - Zhang, Yuzhen

AU - Chan, Paul

AU - Liu, Zhong Min

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Introduction: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest class of drugs to be introduced for the treatment of type 2 diabetes mellitus. These drugs improve glycemic control by increasing urinary glucose excretion and exert additional benefits of weight loss and blood pressure reductions. Areas covered: This review outlines the background to SGLT2 inhibitors and provides details on the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin and discusses the cardiovascular outcome trial. Expert opinion: Empagliflozin was the first from a new group of antidiabetic drugs to show benefits in a cardiovascular outcome trial. There were significant reductions in cardiovascular and all-cause mortality and empagliflozin treatment reduced hospitalizations for heart failure and reduced the progression of diabetic nephropathy. These benefits, which occurred at a very early stage during the study, may be related to a reduction in circulating volume or changes in metabolic fuel utilization in the heart and kidneys. Whether these effects are shared by other SGLT2 inhibitors is not yet known, but there may be differences between drugs related to selectivity for inhibition of SGLT2 compared to SGLT1 or other pharmacological effects. Currently the outcome evidence is only available to support the use of empagliflozin in this drug class.

AB - Introduction: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest class of drugs to be introduced for the treatment of type 2 diabetes mellitus. These drugs improve glycemic control by increasing urinary glucose excretion and exert additional benefits of weight loss and blood pressure reductions. Areas covered: This review outlines the background to SGLT2 inhibitors and provides details on the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin and discusses the cardiovascular outcome trial. Expert opinion: Empagliflozin was the first from a new group of antidiabetic drugs to show benefits in a cardiovascular outcome trial. There were significant reductions in cardiovascular and all-cause mortality and empagliflozin treatment reduced hospitalizations for heart failure and reduced the progression of diabetic nephropathy. These benefits, which occurred at a very early stage during the study, may be related to a reduction in circulating volume or changes in metabolic fuel utilization in the heart and kidneys. Whether these effects are shared by other SGLT2 inhibitors is not yet known, but there may be differences between drugs related to selectivity for inhibition of SGLT2 compared to SGLT1 or other pharmacological effects. Currently the outcome evidence is only available to support the use of empagliflozin in this drug class.

KW - Empagliflozin

KW - SGLT2

KW - sodium-glucose co-transporter 2 inhibitors

KW - type 2 diabetes mellitus

KW - urinary glucose excretion

UR - http://www.scopus.com/inward/record.url?scp=84996551945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996551945&partnerID=8YFLogxK

U2 - 10.1080/17425255.2017.1258401

DO - 10.1080/17425255.2017.1258401

M3 - Article

C2 - 27817207

AN - SCOPUS:84996551945

VL - 13

SP - 211

EP - 223

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 2

ER -